CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference
Rhea-AI Summary
CervoMed (NASDAQ: CRVO), a clinical-stage biotech focused on age-related brain disorders, will participate in a fireside chat and one-on-one investor meetings at the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11, 2026. Management plans to discuss recent progress in the neflamapimod clinical development program. The fireside chat is scheduled from 11:30–11:55 AM ET and will be available via webcast, including through the Investor section of the CervoMed website.
Positive
- None.
Negative
- None.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 09 | Phase 2 enrollment | Positive | +9.7% | Completed enrollment in a 25-patient Phase 2a nfvPPA study. |
| Mar 04 | Phase 3 dosing selection | Positive | +0.3% | Selected 50 mg three-times-daily dosing for the planned DLB Phase 3 trial. |
| Mar 10 | Phase 2b extension results | Positive | +6.3% | Reported positive extension results with improvements versus prior capsules and placebo. |
| Dec 10 | Phase 2b topline data | Negative | -78.9% | Reported failure to achieve statistical significance on primary and key secondary endpoints. |
| Nov 27 | Orphan drug designation | Positive | +14.7% | Received FDA Orphan Drug Designation for neflamapimod in frontotemporal dementia. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Clinical-trial announcements in the tag-specific record were followed by aligned reactions in all five events, although the average move was -9.59%.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the Canaccord Genuity 46th Annual Growth Conference, being held in Boston, MA, on Tuesday, August 11, 2026.
During the fireside chat, management will share recent progress in neflamapimod's clinical development program.
Presentation Details
Format: Fireside Chat
Date: Tuesday, August 11, 2026
Time: 11:30 – 11:55 AM ET
Webcast Link: https://event.summitcast.com/view/WuFmFdTcA9mVsUGHZJFU62/guest_book?session_id=CbcwtmiHhUmzr5EAgGgHjJ
The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/.
About CervoMed
CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed’s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in patients with DLB, enriched for those without AD co-pathology, and the Company announced alignment with the FDA on a potential registration path for neflamapimod in DLB in November 2025. Initiation of a Phase 3 trial in DLB is subject to the establishment of a partnership and/or additional financing. CervoMed also recently completed enrollment in its ongoing Phase 2a clinical trial evaluating neflamapimod in nfvPPA, a subtype of frontotemporal disorders, from which interim biomarker data is anticipated in the early fourth quarter of 2026, and expects the first patient to be dosed with neflamapimod in the EXPERTS-ALS Phase 2a clinical trial in the fourth quarter of 2026.
Contacts
Media:
Lisa Guiterman
Biongage Communications
lisa.guiterman@gmail.com
202-330-3431
Investor Relations:
Argot Partners
cervomed@argotpartners.com
212-600-1902
